08:00 , Dec 8, 2008 |  BioCentury  |  Emerging Company Profile

Verva: Fingerprinting diabetes solutions

Traditional drug discovery for diabetes has begun with identifying a target responsible for triggering a reversible step in the disease pathway, such as dipeptidyl peptidase-4 or peroxisome proliferation activated receptor . Rather than go after...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Company News

Adipogen Pharma, ChemGenex Pharmaceuticals cancer, metabolic news

CXS will spin out its metabolic disease unit, Autogen Research Pty. Ltd., which will merge with Adipogen and be renamed Verva Pharmaceuticals Ltd. CXS will focus on its cancer portfolio, including Ceflatonin homoharringtonine , a...